Related Experiment Video

Updated: Jan 17, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

19.1K

Racial Inequity in Prescription of Semaglutide Among Eligible People With HIV

Andrew W Hahn1, S A Ruderman1, R M Nance1

  • 1University of Washington, Seattle, WA.

Diabetes Care
|September 19, 2025
PubMed

Insights

Semaglutide use is inequitable among people with HIV (PWH). Eligible Black PWH were less likely to receive this medication, indicating disparities in care. Further research is needed to address these gaps.

Area of Science:

  • Medical research
  • Clinical pharmacology
  • Health equity

Background:

  • Semaglutide is increasingly used for weight management and glycemic control.
  • People with HIV (PWH) often have comorbidities like obesity and diabetes, making them potential candidates for semaglutide.
  • Understanding disparities in medication access for PWH is crucial for equitable healthcare.

Purpose of the Study:

  • To investigate the utilization of semaglutide among people with HIV (PWH) who meet medical eligibility criteria.
  • To examine potential racial and ethnic disparities in semaglutide prescription rates within the PWH population.

Main Methods:

  • A cohort of 11,617 people with HIV (PWH) from the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) were assessed for semaglutide eligibility (BMI ≥30 or HbA1c ≥6.5) between 2019 and 2023.
  • Relative risk regression was employed to analyze differences in semaglutide receipt by race and ethnicity, adjusting for demographic factors.

Main Results:

  • Of 11,617 eligible PWH, 6.7% received semaglutide, primarily for obesity (92%) and/or diabetes (62%).
  • Eligible Black PWH were 20% less likely to receive semaglutide compared to White PWH (PR 0.80).
  • This disparity was more significant for Black and Hispanic PWH with higher HbA1c levels (≥8.0).

Conclusions:

  • The study reveals inequities in semaglutide prescribing patterns among people with HIV (PWH).
  • Initiation rates for semaglutide were notably lower in eligible Black PWH, highlighting a critical gap in care.
  • Addressing these disparities is essential for ensuring equitable access to effective treatments for PWH.
Abstract

More Related Videos

Isolation of Exosomes from the Plasma of HIV-1 Positive Individuals06:46

Isolation of Exosomes from the Plasma of HIV-1 Positive Individuals

Published on: January 5, 2016

17.9K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.3K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
257
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
225
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
179
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
587
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
229
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
151